CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Prone position ventilationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Accelerated Prone Position Ventilation of Patients With COVID-19

Prone position ventilation is frequently used in the ICU to treat severe hypoxemia in patients with COVID-19 associated acute respiratory distress syndrome (ARDS). The aim of the PROVENT-COVID study is to assess whether applying prone position ventilation immediately after intubation reduces the duration of mechanical ventilation compared to prone position ventilation according to standard criteria for prone position.

NCT04384900 COVID-19 Procedure: Prone position ventilation

Primary Outcomes

Description: Number of days where patients are alive and not receiving mechanical ventilation

Measure: Days alive without respiratory life support (invasive mechanical ventilation) at day 28.

Time: 28 days after randomization

Secondary Outcomes

Description: Number of days alive and out of hospital

Measure: Days alive and out of hospital on day 28 after randomisation.

Time: 28 days

Description: Number of days where patients are alive and not receiving life support

Measure: Days alive at day 28 without life support (vasopressor/inotropic support, invasive mechanical ventilation or renal replacement therapy).

Time: 28 days

Description: Number of patients with severe adverse reaction

Measure: Number of participants with one or more SARs as described in section 6.1 plus incidence of new persistent nerve injury or grade 3 or 4 (full-thickness skin loss or worse) pressure wounds.

Time: 28 days

Description: Number patients who have died

Measure: 28-days all-cause mortality.

Time: 28 days

No related HPO nodes (Using clinical trials)